KLRA

11.1353.84%
DW

Douglas W. Pagan

Chief Financial Officer

Mr. Douglas W. Pagan, M.B.A., also known as Doug, is Director of TriGemX Bio, Inc. from October 2026. He is Chief Financial Officer of Kailera Therapeutics, Inc. since December 2025. He has experience in finance, investor relations and capital formation across both public and private biopharmaceutical companies. He served as Chief Financial Officer and Chief Operating Officer of Atalanta Therapeutics, Inc. since June 2025 until February 2026 and serves as Director from February 2026. He is the Chief Financial Officer and Chief Operating Officer of Jnana Therapeutics Inc. from April, 2022. He was the Chief Financial Officer of Dicerna Pharmaceuticals, Inc. since May 26, 2020. He served as a Director at ZIOPHARM Oncology Inc. since September 18, 2018 until September 22, 2020. Mr. Pagan served as Chief Financial Officer and Secretary of KSQ Therapeutics since April 2019. He served as the Chief Financial Officer of Paratek Pharmaceuticals, Inc. from December 18, 2014 to April 05, 2019 and served as its Secretary. From April 2008 to December 2014, Mr. Pagan served as Vice President of Finance at Acceleron Pharma, Inc. He joined Acceleron in April 2008. He has served roles in financial and engineering/operations management at leading pharmaceutical companies including Bristol-Myers Squibb and Johnson & Johnson. Prior to joining Acceleron, worked at Biogen Idec as Division Controller with responsibility for reporting, accounting, financial planning and procurement. He also worked in the investment banking division at J.P. Morgan Securities early in his career. Additionally, he has financial transaction experience, having worked in JPMorgan’s healthcare investment banking group. Mr. Pagan holds a B.S.E. in Chemical Engineering from Princeton University and an MBA from Columbia Business School with concentrations in Finance and Accounting.

Positions